eBCa: exercise ups QoL in patients with AI-induced arthralgias

  • Baglia ML & al.
  • Cancer
  • 6 Mar 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The HOPE randomized controlled trial (RCT) finds that postmenopausal hormone receptor (HR)-positive early breast cancer (eBCa) patients with aromatase inhibitor (AI)-induced arthralgias have better QoL with a 1-year gym-based, supervised exercise intervention than do usual-care control patients.

Why this matters

  • HOPE findings suggest that the intervention may prevent treatment discontinuation and increase adherence to AIs.

Study design

  • RCT of exercise, strength training vs usual care in 121 breast cancer survivors receiving AIs and having at least mild arthralgia (defined as a score ≥3 on the Brief Pain Inventory).
  • The intervention consisted of 150 minutes of aerobic exercise and 2 strength training sessions each week for 1 year.
  • The main assessment of QoL was by the Functional Assessment of Cancer Therapy (FACT) questionnaire and its subscales.
  • Funding: NIH; Breast Cancer Research Foundation; Yale Cancer Center.

Key results

  • The exercise group at 12 months had larger improvement than usual care in the following:
    • Overall QoL (27-item FACT-General): 8.0 vs 1.2; P=.002.
    • Breast cancer subscale (27-item FACT-G+10-item breast cancer scale): 2.2 vs 0.7; P=.03.
    • Endocrine subscale (19-item FACT-ES): 5.5 vs 1.7; P=.003.
    • Fatigue (13-item Functional Assessment of Chronic IIlness Therapy [FACIT]-Fatigue): 5.7 vs 0.5; P=.0003.
  • Most outcomes were stronger at 12 than 6 months.

Limitations

  • All items self-reported with potential recall bias.